Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3133367
Max Phase: Preclinical
Molecular Formula: C72H90N18O18S2
Molecular Weight: 1559.75
Molecule Type: Unknown
Associated Items:
ID: ALA3133367
Max Phase: Preclinical
Molecular Formula: C72H90N18O18S2
Molecular Weight: 1559.75
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)[C@@H]1NC(=O)[C@@H](N)CSSC[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2C/C=C/C[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](C)NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N2
Standard InChI: InChI=1S/C72H90N18O18S2/c1-36(2)58-70(105)79-37(3)60(95)83-51(25-40-18-20-44(92)21-19-40)65(100)80-48-16-10-11-17-49(63(98)85-53(26-41-29-76-47-15-9-8-14-45(41)47)69(104)90-59(38(4)91)71(106)88-56(72(107)108)33-110-109-32-46(73)61(96)89-58)81-67(102)54(27-42-30-74-34-77-42)87-68(103)55(28-43-31-75-35-78-43)86-64(99)50(22-23-57(93)94)82-66(101)52(84-62(48)97)24-39-12-6-5-7-13-39/h5-15,18-21,29-31,34-38,46,48-56,58-59,76,91-92H,16-17,22-28,32-33,73H2,1-4H3,(H,74,77)(H,75,78)(H,79,105)(H,80,100)(H,81,102)(H,82,101)(H,83,95)(H,84,97)(H,85,98)(H,86,99)(H,87,103)(H,88,106)(H,89,96)(H,90,104)(H,93,94)(H,107,108)/b11-10+/t37-,38+,46-,48-,49-,50-,51-,52-,53-,54-,55-,56-,58-,59-/m0/s1
Standard InChI Key: LYUFVBMJWDKHPH-NXXAEVANSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1559.75 | Molecular Weight (Monoisotopic): 1558.6122 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Meinander K, Weisell J, Pakkala M, Tadd AC, Hekim C, Kallionpaa R, Widell K, Stenman U, Koistinen H, Narvanen A, Vepsalainen J, Luthman K, Wallen EAA. (2013) Pseudopeptides with a centrally positioned alkene-based disulphide bridge mimetic stimulate kallikrein-related peptidase 3 activity, 4 (3): [10.1039/C3MD20292E] |
Source(1):